Besremi Achieves Strong Market Growth Amid Rising Demand For Polycythemia Vera Treatment
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...
Myelofibrosis (MF) Market Epidemiology and Forecast 2034: JAKAFI Leads Myelofibrosis Market, But New Therapies Poised to Disrupt by 2034
The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...
PharmiWeb9d
Aqilion carries out a rights issue of approximately SEK 26.8 million
The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...
Morningstar9d
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
In addition, JAK inhibitors have been approved in multiple ... JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal transducer ...
Aclaris Therapeutics announces publication describing properties of ATI-2138
Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...